Human LILRB2 Stable Cell Line - HEK293T

The Human LILRB2 Stable HEK293T Cell Line is a cellular model that is derived from the HEK293T cell line, which is a human embryonic kidney cell line. The LILRB2 gene in this cell line has been stably integrated and expressed, allowing researchers to study the function and signaling of the LILRB2 protein. LILRB2 is a member of the leukocyte immunoglobulin-like receptor family and is involved in immune response and inflammation. The stable HEK293T Cell Line is used to investigate the effects of LILRB2 inhibitors, which are potential novel therapies for diseases associated with excessive inflammation or immune response, such as autoimmune diseases and graft-versus-host disease. This cell line has been instrumental in the development of targeted treatments that could improve the outcomes for patients with these conditions.

HEK293 cells were first established in 1978, and the HEK293T variant was derived from these cells in 1987. The “T” in HEK293T stands for “tumor,” indicating that these cells have been immortalized, or made cancerous, by the introduction of the SV40 large T antigen. This transformation allows the cells to grow indefinitely in culture, making them a valuable resource for researchers.

HEK293T cells are known for their high protein expression and easy transfection with various vectors, making them an excellent choice for studying gene function, protein expression, and protein-protein interactions. The cells have a normal karyotype, meaning they have a normal number of chromosomes, and they are negative for the presence of mycoplasma, a bacteria that can contaminate cell lines.